GlobeNewswire

D4t4 Solutions Announces Latest Celebrus Release

Dela

Celebrus Advances Customer Data Platform Leadership Further with New Product Features

  • Latest update consolidates Celebrus as enterprise CDP of choice for banking and insurance sectors
  • Integration with Adobe Experience Cloud augments leading digital marketing platform with streaming customer data
  • New Audience Segmentation feature enables advanced targeting of individuals even when they have left a site or app
  • Latest connector supports creation of Custom Audiences in Google and Facebook
  • Hadoop capabilities extended with enhanced support for Hive open-source data warehouse

SUNBURY-ON-THAMES, United Kingdom, April 19, 2018 (GLOBE NEWSWIRE) --  D4t4 Solutions Plc has announced general availability for the latest release of its leading Celebrus Customer Data Platform (CDP).  Continuing its commitment to creating the industry's most advanced unified system for customer data, Version 8 Update 19 delivers a host of new features that broaden the appeal of Celebrus to enterprises focused on deepening customer engagement.

Adobe Experience Cloud integration for optimising digital marketing

Celebrus has for many years enabled a unified stream of customer data for use in marketing applications.  Now though, this capability is being offered to businesses that have invested in the leading marketing cloud applications from Adobe.  Building on the capabilities already available in Adobe Experience Cloud, the Celebrus Adobe Connector streams data to allow Adobe clients to create genuine 1-to-1 personalisation and real-time customer experiences.

Using Celebrus accelerates the availability of customer behaviour data to Adobe Experience Cloud applications and adds customer experience data for complete coverage of customer interactions across channels.

Audience Segmentation for advanced targeting of individuals

Website or mobile app visitors can now be engaged with at any time, whether they are online or not.  Celebrus enables rules to be run that can regularly sweep offline users like those who have abandoned applications, purchasers who have lapsed for a defined period of time or customers who need to complete a transaction by a particular date.  This creates opportunities to segment and target offline users for re-engagement or remarketing initiatives.

Complete control over when and to whom these rules are run allows optimisation of these segmentation activities and identifies actions for each user like sending them a marketing e-mail, creating a lead for outbound contact or adding them to an audience for advert targeting.

Custom Audience Connector for compliant profiling of Google and Facebook users

The advanced profiling features of Celebrus are now being used to enhance the capabilities of leading ad networks, Google and Facebook.  The new Custom Audience Connector for Google or Facebook supports these networks' audience-building features by enhancing their ability to profile users based on common attributes or similar interests.  This profiling capability enables accurate and compliant retargeting and engagement of customers or can be used to build lookalike audiences for customer acquisition and brand awareness campaigns.

Celebrus not only provides first-party compliant data to enable this feature, overcoming any privacy or permissions concerns that may exist, but it also enables this capability in real-time as well as orchestrating adverts with existing DMPs for the most immediate, accurate and effective campaigns.

Backing for open-source analytics extended with support for Apache Hive

The Celebrus Hadoop Data Loader has been hugely beneficial to clients needing to consume data at scale for advanced customer analytics.  Now this capability has been extended by enabling the creation of tables for Apache Hive data warehouse users, accelerating and simplifying the landing of data into that environment.

This feature speeds up the availability of Celebrus data for data science and analytics initiatives, enabling quicker customer insight and availability of data for marketing applications.

Peter Kear, CEO of D4t4 Solutions Plc, said: "The Customer Data Platform is becoming a mainstream requirement for customer-centric businesses. Sophisticated enterprises are recognising that the success of their customer relationships depends on their ability to unify data from across channels and activate it for use in multiple business applications.  Celebrus captures the very best GDPR-compliant customer data, making it available for marketers, analysts, data scientists and insight experts to drive value throughout their organisations.  I am proud that the latest developments to Celebrus enhance our leadership in this fast-growing space and extend our clients' capacity to operationalise their data for mutually-profitable customer relationships."

The latest version of the Celebrus Customer Data Platform, Version 8 Update 19, is available immediately for new and existing Celebrus clients.

About Celebrus

Celebrus (celebrus.d4t4solutions.com) is the Customer Data Platform from D4t4 Solutions Plc.  Celebrus captures the market's most complete picture of customer behaviour and experience, creating events and profiles in real-time for 1-to-1 personalisation and streaming analytics.  Celebrus is quick and easy to deploy and connects to industry-standard data applications for customer insight and engagement.  Celebrus also gives clients complete control by enabling best-in-class privacy compliance and flexible options for hosting data on-premise or securely in the cloud.

Celebrus is used by global businesses in banking, insurance, retail, travel, automotive and telco industries, collaborating with leading industry partners to drive rapid transformation in customer engagement programmes.

D4t4 Solutions (www.d4t4solutions.com) is ALL ABOUT THE DATA, providing comprehensive products and services that drive value from clients' data assets.  D4t4 Solutions was established in 1985 and is listed on the AIM market of the London Stock Exchange (stock code: D4T4).

Media Contacts

Matthew Tod                                                   
D4t4 Solutions Plc                                         
Tel: +44 (0)1932 893333                             
E-mail: matthew.tod@d4t4solutions.com       

David Hetling
D4t4 Solutions Plc
Tel: +44 (0)1932 893386
E-mail: david.hetling@d4t4solutions.com

This information is provided by RNS
The company news service from the London Stock Exchange

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: D4T4 Solutions PLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum